Specific targeting cancer cells with nanoparticles and drug delivery in cancer therapy

Raj, Sibi; Khurana, Shruti; Choudhari, Ramesh; Kesari, Kavindra Kumar; Kamal, Mohammad Amjad; Garg, Neha; Ruokolainen, Janne; Das, Bina Pani; Kumar, Dhruv

doi:10.1016/j.semcancer.2019.11.002

Cited by 276 publications

(180 citation statements)

References 142 publications

(154 reference statements)

Supporting

Mentioning

158

Contrasting

Unclassified

Order By: Relevance

“…Additionally, mice in this treatment group displayed pale skin (5/7) and exhibited tissue damage at the site of injection (3/7). In mice treated with SSHEL αHER2 , we observed ulcerated tumors (3/7), and one tumor that was larger than 1500 mm 3 . In contrast, treatment with DOX-SSHEL αHER2 resulted in mean tumor size of ~300 mm 3 at day 40.…”

Section: Doxorubicin-encased Sshels Targeting Her2 Inhibit Tumor Growmentioning

confidence: 90%

“…Treatment with SSHEL αHER2 , without drug, had a similar effect on mean tumor size as doxorubicin. However, in mice treated with DOX-SSHEL αHER2 mean tumor size was only ~300 mm 3 . At this concentration of doxorubicin, we did not observe any appreciable signs of toxicity or body weight loss ( Fig.…”

Section: Doxorubicin-encased Sshels Targeting Her2 Inhibit Tumor Growmentioning

confidence: 95%

“…The efficacy of cancer chemotherapeutics can be abrogated by drug clearance and elimination, but also by delivery to non-specific sites, which can be dose-limiting. To diminish this problem, several methods employing nanometer-scale vehicles such as lipid vesicles have been devised to encase cargo for enhanced delivery to malignant cells within the tumor microenvironment [1][2][3] . While these strategies can improve clearance and elimination, they typically rely on passive accumulation of the vehicle near solid tumors where accumulation is due to the abnormal vasculature 4 .…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Cell-specific cargo delivery using synthetic bacterial spores

Kong

Updegrove

Constantino

et al. 2020

Preprint

View full text Add to dashboard Cite

SSHELs are synthetic bacterial spore-like particles wherein the spore's cell surface is partially reconstituted around 1 µm-diameter silica beads coated with a lipid bilayer. Via a unique cysteine engineered in one of the surface proteins, the surface of SSHELs may be covalently decorated with molecules of interest. Here, we modified SSHELs with an affibody directed against HER2, a cell surface protein overexpressed in some breast and ovarian cancer cells, and loaded them with the chemotherapeutic agent doxorubicin. Drug-loaded SSHELs reduced tumor growth with lower toxicity in a mouse tumorxenograft model compared to free drug by specifically binding to HER2-positive cancer cells. We show that SSHELs bound to target cells are taken up and trafficked to acidic compartments, whereupon the cargo is released in a pH-dependent manner. Finally, we demonstrate that SHELLs can clear small tumor lesions in a complex tumor microenvironment in a zebrafish model of brain metastasis. We propose that SSHELs represent a versatile strategy for targeted drug delivery. AUTHOR CONTRIBUTIONS

show abstract

Section: Doxorubicin-encased Sshels Targeting Her2 Inhibit Tumor Growmentioning

confidence: 90%

Section: Doxorubicin-encased Sshels Targeting Her2 Inhibit Tumor Growmentioning

confidence: 95%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Cell-specific cargo delivery using synthetic bacterial spores

Kong

Updegrove

Constantino

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…However, exposure to the concentration of 1.4x10 9 increases GSH levels significantly in MCF-7 cells. antioxidant GSH [18,19].…”

mentioning

confidence: 86%

“…Transporting GSH and other agents to cells in order to reduce the toxic effects of anticancer drugs requires the use of innovative delivery systems [9]. The use of nanotechnology in cancer treatment represents a novel alternative to deliver agents to cells, thanks to the physicochemical properties that many different types of nanoparticles have [10].…”

mentioning

confidence: 99%

Chitosan-Glutathione nanoparticles modify oxidative stress induced by doxorubicin in breast cancer cells

López-Barrera¹,

Díaz-Torres²,

Martínez-Rosas³

et al. 2020

Preprint

View full text Add to dashboard Cite

Doxorubicin is a widely used antineoplastic agent for the treatment of various types of cancer. However, it is also a highly toxic drug because it induces the generation of oxidative stress. Thus, the use of antioxidant molecules has been considered to reduce the toxicity of doxorubicin. In this report, we investigated whether the use of chitosan-glutathione (CH-GSH) nanoparticles could reduce cell damage induced by doxorubicin on breast cancer cells. CH-GSH NPs were characterized in size, Zeta potential, concentration, and shape. When breast cancer cells were treated with CH-GSH nanoparticles, these were localized in the cellular cytoplasm. Combined exposure of doxorubicin and nanoparticle increased intracellular GSH levels while decreasing reactive oxygen species and malondialdehyde levels. The antioxidant enzyme activity was also decreased. Together our data suggest that the use of CH-GSH nanoparticles can reduce the oxidative stress induced by doxorubicin on breast cancer cells.

show abstract

Targeted Cancer Therapy‐on‐A‐Chip

Abed,

Radha,

Anjum

et al. 2024

Adv Healthcare Materials

View full text Add to dashboard Cite

Targeted cancer therapy (TCT) is gaining increased interest because it reduces the risks of adverse side effects by specifically treating tumor cells. TCT testing has traditionally been performed using two‐dimensional (2D) cell culture and animal studies. Organ‐on‐a‐chip (OoC) platforms have been developed to recapitulate cancer in vitro, as cancer‐on‐a‐chip (CoC), and used for chemotherapeutics development and testing. This review explores the use of CoCs to both develop and test TCTs, with a focus on three main aspects, the use of CoCs to identify target biomarkers for TCT development, the use of CoCs to test free, un‐encapsulated TCTs, and the use of CoCs to test encapsulated TCTs. Despite current challenges such as system scaling, and testing externally triggered TCTs, TCToC shows a promising future to serve as a supportive, pre‐clinical platform to expedite TCT development and bench‐to‐bedside translation.

show abstract

Specific targeting cancer cells with nanoparticles and drug delivery in cancer therapy

Cited by 276 publications

References 142 publications

Cell-specific cargo delivery using synthetic bacterial spores

Cell-specific cargo delivery using synthetic bacterial spores

Chitosan-Glutathione nanoparticles modify oxidative stress induced by doxorubicin in breast cancer cells

Targeted Cancer Therapy‐on‐A‐Chip

Contact Info

Product

Resources

About